As of 9:33:05 AM EST. Market Open.
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 2 | 4 | 4 |
| Avg. Estimate | -0.78 | -0.81 | -2.69 | -3.55 |
| Low Estimate | -0.93 | -0.81 | -2.9 | -3.8 |
| High Estimate | -0.72 | -0.8 | -2.53 | -3.34 |
| Year Ago EPS | -30.76 | -0.7 | -32.38 | -2.69 |
Revenue Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 1 | 3 | 3 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | 0.00% | 0.00% | 0.00% |
Earnings History
| Currency in USD | 12/31/2023 | 3/31/2024 | 6/30/2024 | 9/30/2024 |
|---|---|---|---|---|
| EPS Est. | -0.65 | -1.3 | -0.59 | -1.07 |
| EPS Actual | -30.76 | -0.7 | -0.65 | -0.61 |
| Difference | -30.11 | 0.6 | -0.06 | 0.46 |
| Surprise % | -4,632.31% | 46.00% | -10.47% | 42.83% |
EPS Trend
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.78 | -0.81 | -2.69 | -3.55 |
| 7 Days Ago | -1.08 | -0.79 | -3.01 | -2.93 |
| 30 Days Ago | -0.81 | -0.74 | -3.35 | -2.93 |
| 60 Days Ago | -0.81 | -0.74 | -3.35 | -2.93 |
| 90 Days Ago | -0.89 | -0.74 | -3.29 | -2.9 |
EPS Revisions
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | -- | 1 | -- |
| Up Last 30 Days | 1 | -- | 1 | -- |
| Down Last 7 Days | -- | 3 | -- | 1 |
| Down Last 30 Days | -- | 2 | -- | 1 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| AVBP | 97.46% | -15.00% | 91.68% | -31.72% |
| S&P 500 | 5.00% | 12.00% | 2.10% | 12.20% |
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 11/15/2024 |
| Maintains | Citigroup: Buy to Buy | 9/11/2024 |
| Reiterates | Oppenheimer: Outperform to Outperform | 9/10/2024 |
| Maintains | Goldman Sachs: Buy to Buy | 9/10/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 9/10/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 8/16/2024 |
Related Tickers
ANRO Alto Neuroscience, Inc.
3.8300
0.00%
KYTX Kyverna Therapeutics, Inc.
4.4200
0.00%
GUTS Fractyl Health, Inc.
2.0237
-0.80%
APGE Apogee Therapeutics, Inc.
44.33
-0.39%
DNTH Dianthus Therapeutics, Inc.
23.90
+0.38%
CGON CG Oncology, Inc.
28.69
-0.26%
TYRA Tyra Biosciences, Inc.
14.78
-1.07%
SYRE Spyre Therapeutics, Inc.
23.44
-2.77%
MBX MBX Biosciences, Inc.
19.90
+5.07%
LXEO Lexeo Therapeutics, Inc.
6.84
-0.58%